Navigation Links
Pieris Progresses Development of its Proprietary Biotherapeutics,Platform: Successful Demonstration of Dual Targeting With,Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin(R) technology has successfully demonstrated dual targeting potential.

Commenting on this development, Dr Andreas Hohlbaum, Director of Science and Preclinical Development of Pieris said: "As Pieris continues to validate the therapeutic application of its technologies, dual targeting is viewed as a major step forward. Combining the benefits of bivalent, avid binding of disease targets with the ability to modulate two targets at once shows the clear development potential of the Duocalin(R) technology to treat multi-factorial diseases".

Using individual monomeric Anticalins(R) selected to have picomolar binding affinity to distinct determinants on two defined clinically validated targets, Pieris has constructed Duocalins(R) as monomeric, bivalent binding proteins that retain target specificity and affinity regardless of the structural orientation of their binding domains. Furthermore, the high intrinsic stability of Duocalins(R) is comparable to monomeric Anticalins(R), offering flexible formulation and delivery potential for Duocalin(R)-based drug candidates.

Despite the low molecular weight of monomeric Anticalins(R) relative to antibodies, their core scaffold provides a highly selective binding site with high structural plasticity and an extensive binding surface comparable to that achieved with antibodies. The adaptability of the Anticalin(R) scaffold has already allowed Pieris to develop therapeutic and diagnostic product candidates with custom designed functionality. Duocalins(R) allow multiple targets to be bound and modulated through a single molecule, which is particularly advantageous in diseases known to involve more than a single causative factor. Moreover,
'"/>




Page: 1 2 3

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies
3. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
4. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
7. CuraGen Presents Update on Clinical Development Program for Belinostat
8. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
11. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
Post Your Comments:
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... 2011 VWR Funding, Inc., the parent company ... supply and distribution company, will hold a conference ... its first quarter 2011 financial results. ... President and CEOGregory L. Cowan , Senior Vice ...
... 6, 2011 SaveRxCanada.com the premier Canadian pharmacy intermediary ... Canada drugs from a Canada pharmacy . ... drugs can be 85% less than the U.S. price and ... 2002. 2. Convenience – Many patients are elderly and ...
Cached Medicine Technology:VWR to Hold First Quarter 2011 Financial Results Conference Call 2Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 State Forestry ... data management system with support from GEOSYSTEMS, a dedicated ... new solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... data as well as point clouds and documents. This ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... countries will share ideas on manufacturing techniques for ... industry sectors at the third International Conference On ... , Burak O. Ozdoganlar, ICOMM,08 chair and ... at Carnegie Mellon, said the conference is a ...
... First year college students believe that occasional nonmedical use ... than cocaine, but more risky than marijuana or consuming ... a new study published in the September issue of ... Society for Prevention Research., This is the first study ...
... Sept. 2 A sudden sharp increase in ... concern for parents and,healthcare professionals. Here,s more on ... Listen to this report from Nationwide Children,s Hospital ... video, audio, text, graphics and,photos for free and ...
... Award-winning online program helps schools better comply with federal ... health issues, LANCASTER, Pa., Sept. 2 For ... could be lower than our own. The,Centers for Disease ... prevalence of overweight and obesity has increased,sharply for both ...
... Costs and ... Improve Patient Outcomes Together, HOUSTON, Sept. 2 US ... division that offers a first-time,opportunity for oncologists and health plans ... of cancer,care. With a unique focus on supporting the entire ...
... took benefit of nation,s 1st such law, passed in 2004 ... chronically ill kids have made use of California,s pioneering paid ... aware it exists, according to researchers at the Rand Corp. ... leave law. It is funded by employees through an automatic ...
Cached Medicine News:Health News:Carnegie Mellon to host micromanufacturing conference 2Health News:College freshmen: pain killers and stimulants less risky than cocaine; more risky than marijuana 2Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 2Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 3Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 4Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 5Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 6Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Paid Family Leave Program Goes Mostly Unused 2
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: